Expressão gênica dos fatores de crescimento fibroblástico 7 e 10 (FGF-7 e FGF-10) ao longo do desenvolvimento folicular ovariano bovino

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Novos inibidores peptídicos de topoisomerases bacterianas estruturalmente derivados da proteína CcdB

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Síntese, caracterização e estudo da atividade antitumoral de complexos de paládio(II) com ligantes sulfurados e trifenilfosfina

Pós-graduação em Química - IQ

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.

Geostatistics and remote sensing methods in the classification of images of areas cultivated with citrus

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Peptídeos derivados da toxina ParE: síntese, estrutura e estudos de inibição de DNA topoisomerases

Pós-graduação em Biotecnologia - IQ

Metodologias e estratégias de imputação de marcadores genéticos em bovinos da raça Cachim

Pós-graduação em Genética e Melhoramento Animal - FCAV

Espécies metalo-supramoleculares discretas polinucleares: sínteses e caracterização

Pós-graduação em Química - IQ

Grau de comprometimento e tempo de trânsito orofaríngeo em disfagia no acidente vascular encefálico

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Diagnóstico, tratamento e seguimento do carcinoma medular de tireoide: recomendações do Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Cross-cultural adaptation of Preschool Language Assessment Instrument: Second Edition

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Translation and cultural adaptation of Brazilian Detailed Assessment of Speed of Handwriting: conceptual and semantic equivalence

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Human-calf relationship and its implications on animal welfare

Pós-graduação em Zootecnia - FCAV

Prevalência da excreção e caracterização molecular do poliomavírus humano JC em amostras de urina de pacientes com aids sem leucoencefalopatia multifocal pro-gressiva

The human poliomavirus is the etiologic agente of Progressive multifocal leukoencephalopathy (PML), a disease characterized by focal lesions not expansives of the central nervous system that develops in imunocompromissed patients, specially people with aids. The main aim of the study was to evalute the prevalence of the JCV excretion in urine samples of patients with aids, without PML, to compare two JCV DNA detection techniques through of two diferents genomic regions and to evaluate the genotypic characterization of the positive samples. A total of 75 samples were colected in the Instituto de Infectologia Emílio Ribas, in Sao Paulo, Brazil, between may and november, 2009. To detect the JC virus it was made the DNA extraction and then the polimerase chain reaction (PCR). Firstly a fragment of 215 bp was amplified, which corresponds to the codifying gene of the strutural protein of de JC vírus capsid VP1. All the samples were later submitted to another PCR that uses a pair of primers complementaries to the early region of the JCV (T antigen) amplifying a fragment of 173 bp. Followed by the digestion of the amplified product with the restriction enzime BamH1, resulting in two smaller fragments (120 bp and 53 bp). The JC vírus was detected in 53 samples, for both techniques (70,7% for VP1 PCR, and the restriction enzime BamH1), 34/46 were men (73,9%) and 19/29 were women (65,5%). The JCV excretion was higher in individuals that were over 46 years old. Regarding the seven genotypes described in the literature, the ones that were more prevalent among the JC positive patients were 3B and 3A with 10 samples each (21,0%), the 2B with 9 samples (19,0%) and genotype 6, with six samples (13,0%). As in the brown patients as the white ones, the most prevalent genotype was 3B. In the present study it was observed a high prevalence of JCV DNA (70,7%) and the genotype 3 (43,0%)... (Complete abstract click electronic access below)

Síntese e aplicações de inibidores peptídicos de topoisomerases associados a sistemas de liberação controlada de fármacos

O uso de novas tecnologias para o desenvolvimento de medicamentos constitui uma estratégia promissora no campo da biotecnologia. Nesse sentido, peptídeos com efeito antimicrobiano, produzidos por plantas, animais e microrganismos estão sendo utilizados como modelos para o desenvolvimento de novos medicamentos com aplicações em saúde. Resultados promissores têm sido obtidos em relação à inibição da atividade das enzimas bacterianas DNA girase e topoisomerase IV por derivados peptídicos de toxinas bacterianas, comprovados em ensaios in vitro. Porém, ensaios in vivo não demonstraram reprodutibilidade, basicamente devido à baixa permeabilidade da célula bacteriana a estes compostos. Desta forma, o objetivo deste projeto consiste em aplicar sistemas eficientes para promover o acesso de moléculas peptídicas sintéticas derivadas de toxinas bacterianas, ao meio intracelular e, consequentemente, aos seus alvos intracelulares: as enzimas DNA girase e/ou topoisomerase IV. Com isso, pretendemos solucionar a barreira técnica em que se encontram as aplicações dessa classe de biomoléculas como precursores de novos agentes antibacterianos, o que certamente causaria um importante avanço nas pesquisas desenvolvidas pelo grupo